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Original Article

Follow-Up of Patients after Stereotactic Radiation for
Lung Cancer
A Primer for the Nonradiation Oncologist
Kitty Huang, MSc, MDCM,* and David A. Palma, MD, MSc, PhD, FRCPC,*† on Behalf of the IASLC
Advanced Radiation Technology Committee

Background: The use of stereotactic ablative radiotherapy (SABR)
as primary treatment for early stage non–small-cell lung cancer, or
for ablation of metastases, has increased rapidly in the past decade.
With local recurrence rates reported at approximately 10%, and a
patient population that is becoming increasingly fit and amenable to
salvage treatment, appropriate multidisciplinary follow-up care is
critical. Appropriate follow-up will allow for detection and management of radiation-related toxicity, early detection of recurrent disease and differentiation of recurrence from radiation-induced lung
injury.
Methods: This narrative review summarizes issues surrounding
follow-up of patients treated with SABR in the context of a multidisciplinary perspective. We summarize treatment-related toxicities including radiation pneumonitis, chest wall pain, rib fracture,
and fatal toxicity, and highlight the challenges of early and accurate
detection of local recurrence, while avoiding unnecessary biopsy or
treatment of benign radiation-induced fibrotic lung damage.
Results: Follow-up recommendations based on the current evidence
and available guidelines are summarized. Imaging follow-up recommendations include serial computed tomography (CT) imaging
at 3–6 months posttreatment for the initial year, then every 6–12
months for an additional 3 years, and annually thereafter. With suspicion of progressive disease, recommendations include a multidisciplinary team discussion, the use of high-risk CT features for accurate
detection of local recurrence, and positron emission tomography/CT
SUVmax cutoffs to prompt further investigation. Biopsy and/or surgical or nonsurgical salvage therapy can be considered if safe and when
investigations are nonreassuring.
Conclusions: The appropriate follow-up of patients after SABR
requires collaborative input from nearly all members of the thoracic
multidisciplinary team, and evidence is available to guide treatment
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decisions. Further research is required to develop better predictors of
toxicity and recurrence.
(J Thorac Oncol. 2015;10: 412–419)

S

tereotactic ablative radiotherapy (SABR), also known as
stereotactic body radiotherapy (SBRT), has become a standard treatment for inoperable, early stage non–small-cell lung
cancer (NSCLC). SABR uses highly conformal radiotherapy
plans, with rigorous patient setup procedures, to deliver large,
ablative doses of radiotherapy in only a few treatment sessions,
often between 1 and 8 fractions (Fig. 1). SABR differs from
older radiotherapy techniques in several regards: overall treatment time is much shorter (usually 1–2 weeks duration versus
4–6 weeks, respectively); the dose per fraction is much larger
(often 18 Gy per day, rather than 2 Gy per day, respectively);
and SABR treatment plans allow for large “hot spots” within
the tumor, sometimes more than 150% of the prescribed dose.
These differences in treatment planning and delivery are
associated with increased biologic potency: local control rates
after SABR are often reported as ~90% at 3 years.1,2 In light
of these promising outcomes, and the relative convenience
of SABR delivery using only a few fractions in an outpatient
setting, the use of SABR in clinical practice for treating primary lung cancers and oligometastatic disease has increased
rapidly.3–5 These high rates of local control have led to suggestions that SABR may be as effective as surgical resection
for the primary treatment of T1N0 or T2N0 NSCLC,6 a suggestion that has led to debate and the launch of randomized
comparisons with lobectomy or wedge resection as primary
treatment in operable patients.6,8 Unfortunately, three such
randomized trials have closed because of a lack of accrual;
as a result, randomized comparisons with surgery will not be
available in the near future.
The assessment of patients after SABR is an increasingly common scenario for the multidisciplinary team: not
only are increased numbers of inoperable patients receiving
SABR for lung cancer or oligometastatic disease but the use
of SABR for borderline or potentially operable patients is also
increasing.8 SABR recipients are increasingly fit with longer
life expectancies, resulting in increased opportunity for surgical or nonsurgical salvage. For patients with local progression
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FIGURE 1. 90-year-old man with
severe COPD (GOLD III) presents
with a biopsy-proven left lung cancer, treated with stereotactic radiotherapy (54 Gy in three fractions).
Representative axial images correspond to: A, PET/CT. B, Patient setup,
with ConeBeam CT matched to planning CT to confirm setup accuracy. C,
SABR treatment plan. COPD, chronic
obstructive pulmonary disease; PET,
positron emission tomography; CT,
computed tomography; SABR, stereotactic ablative radiotherapy.

detected after SABR, several options may be associated
with long-term survival, including surgical resection, targeted agents for patients harboring oncogene mutations, or
in selected cases, repeat irradiation.9–11 These posttreatment
decisions often require collaboration between members of the
thoracic multidisciplinary team, including radiation oncologists, surgeons, radiologists, pulmonologists/respirologists,
pathologists, and medical oncologists. This overview will discuss common clinical and radiologic findings after SABR to
help guide these multidisciplinary decisions.

Radiation Pneumonitis after SABR
With older conventional radiotherapy techniques for
lung cancer, reported rates of radiation pneumonitis (RP) often
ranged from 13% to 37%.12 Symptomatic RP is characterized
by cough or dyspnea, often accompanied with fever, chest
discomfort and pleuritic pain, sometimes requiring oxygen
or hospitalization. Alternative diagnoses include infection,
chronic obstructive pulmonary disease (COPD) exacerbation, recurrent tumor, lymphangitic carcinomatosis, among
other entities,13 and in approximately 50% of cases, accurate

diagnosis of RP is difficult.14 The standard first-line treatment
of symptomatic RP is oral corticosteroid therapy. Response
is usually rapid, and response rates of up to 80% have been
reported.15 Less commonly, intravenous corticosteroids, oxygen support, and hospitalization may also be required. When
discontinuing steroid therapy, slow tapering of corticosteroid
is important to prevent relapse of symptoms.16
Because of the relatively small lung volumes irradiated
to high doses during SABR, the development of dyspnea or
RP after SABR is uncommon. In a multicenter prospective
trial of 55 patients with inoperable stage I NSCLC receiving
SABR (RTOG 0236),17 the rate of grade 3 or 4 pulmonary
or respiratory-tract-specific toxicity was 16%, and the rate of
protocol-specified hypoxia or pneumonitis was 8%. In a metaanalysis of 11 observational studies of SABR (mostly prospective), the rate of severe (grade ≥ 3) RP following SABR
was only 2%, with 0.8% of patients developing irreversible
dyspnea.18
A recent randomized trial of 102 patients with T1 or
T2N0 NSCLC compared stereotactic radiotherapy (66 Gy in
three fractions) versus high-dose conventional radiotherapy
(70 Gy in 35 fractions over 7 weeks). In the conventional arm,
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a 2 cm margin (compared with 0.5 cm for SABR) was added
around the tumor to account for targeting uncertainties with
the older technique. The trial, reported thus far in abstract form
only, demonstrated that with these large margins, conventional
RT was able to achieve similar local control as SABR, but
with increased toxicity (RP rates 16% in the SABR arm versus 34% in the conventional arm). SABR was favored due to
lower toxicity and much shorter treatment duration.19
SABR appears to be well tolerated in patients with
severe COPD, regardless of oxygen dependence. In a retrospective study of 265 patients treated with SABR, the risk
of RP ≥ Grade 1 was lower in patients with severe COPD,
defined as a Global Initiative for Chronic Obstructive Lung
Disease (GOLD) score of III or IV (odds ratio [OR] of RP
0.37 for GOLD III, compared with patients with GOLD 0, p
< 0.01).20 Treatment-related mortality is also low: a systematic review of the literature comparing surgery to SABR in
176 patients with severe COPD (defined as GOLD score III
or IV or a predicted postoperative forced expiratory volume
in 1 second (FEV1) of ≤ 40%), showed a 30-day mortality
of 10% versus 0% respectively, favoring SABR. Local and
locoregional control rates were excellent in all identified studies with either surgery or SABR (≥ 89%).21
Certain subgroups of patients may be at higher risk of
RP, including patients with large tumors, and those with interstitial lung disease (ILD). In a small study of 18 patients with
large tumors (defined as a planning target volume greater than
80 cc) treated with SABR, the crude risk of RP was 26%, and
was closely correlated with several factors, particularly the
volume of contralateral lung receiving a low-dose bath (≥ 5
Gy) of radiation.22 In one study, ILD was associated with an
increased risk of severe and fatal RP of 26% versus 3% (crude
rates, p < 0.001).23 Because many patients with ILD are also
at high risk of operative morbidity and mortality, SABR can

be reasonably considered with caution after a patient discussion regarding risks and benefits, and attempts to optimize a
patient’s baseline status before treatment.
Studies reporting on effects of SABR on pulmonary
function show only small declines in pulmonary function. A
retrospective study of 141 patients treated with SABR who
underwent pre- and posttreatment pulmonary function tests
(PFTs) detected only small declines in FEV1 or forced vital
capacity (FVC), with statistical significance limited to patients
with good baseline pulmonary function (i.e., mild/moderate
COPD).24 Nonsignificant declines in FEV1 were reported in
another study of 92 patients, with declines in FEV1 of 1.88%
predicted and in carbon monoxide diffusion capacity (DLCO)
of 2.59% predicted.25 In RTOG 0236 described above, the mean
decline in percent predicted FEV1 was 5.8% and in DLCO was
6.3% at 2 years, which did not meet statistical significance.
Furthermore, baseline PFTs did not predict pulmonary toxicity
or overall survival.26 Patient-reported quality-of-life data also
confirms a lack of quality-of-life decline after SABR.27

Radiographic Patterns of Lung
Injury Following SABR
Although symptomatic RP after SABR is uncommon,
radiographic radiation-induced lung injury (RILI) occurs
frequently, as a result of the ablative doses of radiotherapy
delivered to the peritumoral region. RILI can mimic a local
recurrence (Fig. 2) both in morphologic appearance and time
course, leading to an important clinical dilemma: how to
accurately distinguish recurrence from fibrosis and determine
when a biopsy or other intervention is warranted. This distinction is particularly important for an increasingly fit SABR
patient population, where salvage options may still be considered, including surgical resection, reirradiation, combined
chemoradiotherapy, or palliative local or systemic therapy.

FIGURE 2. SABR plan and follow-up
imaging for the patient described in
Figure 1. Serial CT chest follow-up
were scans obtained at 3, 9, 15, 22,
32, 35, and 39 months after radical
treatment. The patient was not a
candidate for salvage interventions
and thus was monitored throughout
without repeat biopsy. There was
no change in RECIST measurement
beyond 32 months. SABR, stereotactic ablative radiotherapy; CT,
computed tomography.
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Inaccurate classification as benign radiation lung injury can
confound timely detection and delay treatment of disease progression. Alternatively, inaccurate classification of RILI as
local recurrence can lead to unnecessary biopsy or even salvage treatment with its associated risk of morbidities; biopsy
or resection of pseudoprogression has been reported in several
case studies in the literature.28–30
RILI can be classified as RP in the acute setting (within
6 months of treatment), and pulmonary fibrosis in the late setting (after 6 months and beyond). The degree of lung injury
depends on multiple factors, including total dose and fractionation of irradiation, along with target size.31 RILI is reported to
occur in 62% of patients treated with SABR in the acute setting,
and in 91% of patients in the late setting, with the majority of
patients remaining clinically asymptomatic.32 Radiologic signs
of fibrosis can potentially evolve even 2 years after treatment
or beyond and does not follow a known predictable course.33
Common patterns encountered on computed tomography
(CT) radiographic imaging have been classified as, in the acute
setting: consolidative or ground-glass opacity changes, each
subdivided into diffuse (greater than 5 cm) or patchy (≤ 5 cm),
and in the late setting: modified conventional, mass-like, or scarlike patterns.33–35 Despite this distinct range of morphologies,
these categories are not generally used to predict recurrence.
Furthermore, considerable interphysician variability in assessments can result from the subjective nature of the current image
evaluation criteria.36 However, familiarity with common patterns of RILI may help facilitate diagnosis of local recurrence.

A systematic review has identified certain radiographic
high-risk features (HRFs) suggestive of recurrence after SABR
as per Table 1.32,43 To reduce the potential bias associated with
imaging-defined recurrences, HRFs were validated using CT
datasets from known pathology-proven recurrences, who were
matched to nonrecurrences, in a blinded study.43 The best HRFs
in terms of both sensitivity and specificity were enlargement
after 12 months and cranio-caudal growth of ≥ 5 mm and ≥ 20%
(Table 1). The presence of three or more HRFs predicted local
recurrence with high sensitivity and specificity (over 90%).
Functional imaging by FDG-PET can complement suspicious CT findings, although FDG avidity can appear transiently following SABR and even persist at a low value for
over 12 months.32 Lung injury following ablative radiotherapy can result in transiently increased metabolically activity
resulting in false-positive FDG avidity. Such FDG avidity may
lead to unnecessary biopsy of benign inflammatory tissue and
has been described as “pseudoprogression” in several case
reports.29,44 Falsely elevated SUVmax readings of up to 7.0 has
been detected shortly following SABR treatment in patients
who ultimately were not classified as having progressive disease.45 Although the data is highly heterogeneous, a posttreatment SUVmax ≥ 5.0, or greater than the original pretreatment
SUVmax appears most suggestive of recurrent disease.32,46–48
In another study with 17 local recurrences, SUVmax cutoffs as
low as 3.2 and 4.2 have been reported, with sensitivity and
specificity of 100% and 96–98%, respectively; however, not
all recurrences were pathologically proven.49

Challenges in Response Assessment

Other Adverse Effects of SABR

All follow-up imaging modalities have limitations
in response assessment in the post-SABR setting. With CT
alone, benign changes may appear as an evolving mass-like
opacity, easily mistaken for local recurrence.33,37 The standard
evaluation of tumor response by Response Evaluation Criteria
in Solid Tumors (RECIST) 1.1 presents challenges in the postSABR setting, because these criteria rely on diameter alone to
classify response, and increasing areas of fibrosis may meet
the criteria for progressive disease. RECIST measurements
should be done in the plane of image acquisition (axial for
body CT).38 Positron emission tomography (PET) also has limitations: acute inflammatory reaction within lung parenchyma
exposed to ablative doses of radiation can result in falsely
elevated metabolic activity suggestive of malignancy.39,40 PET
is more costly than CT and is not often a routine posttreatment
investigation at many centers; and standardized uptake value
(SUV) measurements are not fully quantitative and are dependent on more complex standardization procedures.41
Studies reporting on imaging predictors of response
after SABR are limited by the lack of pathologic proof of
recurrence for many patients, because of the relative frailty of
the SABR patient population and/or the avoidance of biopsy
where there is a lack of options for salvage in the event of
a positive result. This lack of pathologic proof of recurrence
may introduce bias, creating a circular argument whereby
imaging is used to define the recurrence endpoint, and then
the same imaging modality is investigated as a predictor of
recurrence, overestimating the predictive ability of such tests.

Patients receiving SABR are also at risk of nonpulmonary adverse effects. Approximately one-third of patients
will experience fatigue,50 which is usually self-limiting.
Uncommon acute or sub-acute adverse effects can include
skin toxicity, chest wall pain (CWP), and nausea, whereas
late effects can include ongoing CWP, rib fracture, and rarely,
injury to the mediastinal structures when SABR is delivered
to centrally located tumors.
The incidence of CWP and rib fracture can be mitigated using a risk-adapted treatment strategy, whereby the
risk of toxicity for tumors adjacent to the chest wall can be
minimized by giving SABR over more fractions (i.e., using
a smaller daily dose). Based on radiobiological modeling,
TABLE 1. High-Risk Features on CT Predictive of
Local Recurrence43
High-Risk Feature
Enlarging opacity at primary site
Sequential enlargement
Enlargement after 12 months
Bulging margin
Linear margin disappearance
Loss of air bronchogram
Cranio-caudal growth of ≥5 mm
and ≥20%

Specificity (%)

92
67
100
83
42
67
92

67
100
83
83
100
96
83

CT, computed tomography.
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smaller daily fraction sizes can substantially decrease the risk
of late side effects.51 In a study cohort of 42 patients treated
with stereotactic radiotherapy doses of 54–60 Gy delivered
over only three fractions to all patients regardless of tumor
location, high rates of chest wall toxicity were observed, with
nine patients developing rib fracture.52 Alternatively, using a
risk-adapted radiation treatment scheme as described above
and delivering 55 Gy over five fractions (two additional fractions) for tumors abutting the chest wall, lower toxicity rates
have been achieved, with reported CWP and rib fracture of
only 11.4% and 1.6%, respectively.53 A separate study of
69 patients used a similar risk-adapted approach, delivering either 54 Gy in three fractions, or 50–60 Gy in five fractions, the latter in patients with significant chest wall dose.
The authors report a low incidence of chest wall toxicity at
20 months posttreatment, with chest wall pain in six patients
(8.3%; one [1.4%] grade 3, as per CTCAE version 4.0) and rib
fracture in five patients (6.9%).54
Fatal toxicity has been reported in the treatment of central
tumors or tumors located within 2 cm of major structures such
as the bronchial tree, trachea, or major vessels—accordingly
termed the “no fly zone” in SABR—particularly when such
tumors are treated with three-fraction regimens. These excessive toxicities were most notably reported in a prospective
phase II trial of medically inoperable early stage lung cancer
of 70 patients, where patients were treated with the equivalent
of approximately 54 Gy in three fractions, and the 2-year freedom from severe toxicity was 83% for patients with peripheral
tumors and only 54% for patients with central tumors.55 In a
4-year update, severe toxicities occurred in 10.4% of patients
with peripheral tumors and 27.3% of patients with central
tumors (p = 0.088).56 A case of central airway necrosis following SABR treatment to a central tumor has also been well
described.57 The risk of severe toxicity appears to be closely
related to dose and fractionation. In a systematic review of
315 patients with centrally located tumors treated by SABR
using various fractionation schemes, overall treatment-related
mortality rate was reported at 2.7% and rates of Grade 3 or 4
toxicities were less than 9%.58 The authors observed a dose–
response relationship for toxicity, with a 75% reduction in
treatment-related mortality (from 2.7% to 1%) when patients
receive a lower biologically effective dose, ≤ 210 Gy3 (a measure of the biologic effect of radiation on a particular tissue,
taking into account radiation dose per fraction and total dose).
In a recent study of 100 patients with centrally located tumors,
the most common toxicity was chest wall pain (18% grade 1,
13% grade 2) followed by RP (11% grade 2, 1% grade 3) with
no grade 4–5 toxicity noted.59 For a more in-depth review of
the issues regarding treatment of central tumors with stereotactic radiation, the reader is referred to the relevant article in
this IASLC series.60
Toxicities related to SABR in a reirradiation scenario,
either as primary or salvage treatment for local recurrence, a
secondary lung primary, or metastases, has been described in
a limited number of small retrospective studies and in a systematic review. In a study of 39 patients who were treated with
salvage SABR following conventional radiotherapy, 23% of
patients had grade 2–3 RP, 3% had grade 4 skin toxicity, and
no grade 5 toxicity was reported.61 In a similar larger study
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of 72 patients, salvage SABR following prior radiotherapy
resulted in 20.8% of patients with severe RP (≥ grade 3), with
one grade 5 fatality (~1%). Grade 5 toxicity rates, however,
vary greatly among studies and fatality has been reported in as
high as 12% of patients.62 In a repeat SABR scenario, Peulen
et al. reported on 32 lesions in 29 patients, with 17% grade
4–5 toxicity and 10% (n = 3) grade 5 toxicity consisting of
massive hemoptysis. Notably, all patients with severe toxicity had centrally located tumors. Overall in the systematic
review, of 19 studies involving 466 patients that reported on
SABR in various reirradiation scenarios, the rates of grade
1–3 RP, grade 4 toxicity and fatal toxicity was reported in 124
(27%), 2 (less than 1%) and 8 patients (1.7%), respectively.62
The data suggests that toxicity may be increased in a repeat
reirradiation scenario and repeat SABR should be considered
with caution. Given most fatal toxicities occurred in patients
treated for centrally located tumors, repeat irradiation of such
lesions should be avoided or given with caution.
Toxicities following the treatment of multiple primary
lung cancers by SABR have also been reported. In one study,
synchronous lesions treated to a dose of 54–60 Gy in 3–8 fractions were described in 56 patients, and no Grade 4–5 toxicities
were observed after a median follow-up of 44 months.63 Given
a favorable toxicity profile, and 85% lesional control rates, the
authors conclude multiple SABR treatments for multiple primary lung cancers without nodal metastasis can be considered
as a radical treatment option. Another study where SABR represented the second treatment after an index/dominant tumor
was treated by any modality, grade ≥ three RP was also low,
reported in 2 of 71 patients (3%).64

General Follow-Up Recommendations
Follow-up recommendations, including the frequency
and duration of follow-up imaging for lung cancer survivors,
are based nonrandomized studies. A retrospective study on
the patterns of recurrence following SABR in a large cohort
of 124 patients with disease recurrence from the Netherlands
showed the vast majority of recurrences occurred within the
first 3 years after treatment1; a corresponding posttreatment
CT imaging follow-up has been proposed at 6-month intervals
for the first 3 years, and annually thereafter.
Published consensus guidelines are also available. The
American Association for Thoracic Surgery guidelines, applicable to lung cancer survivors eligible for additional therapy,
recommend high-resolution surveillance CT scans every 6
months during an initial 4-year surveillance period; in the
absence of concerning signs of recurrent disease, the frequency of follow-up imaging can be reduced to an annual lowdose screening CT, to account for the risk for a second lung
cancer diagnosis of 3% per year.65 National Comprehensive
Cancer Network guidelines recommend imaging surveillance
with a chest CT scan (contrast optional) every 6–12 months for
2 years, then a noncontrast-enhanced chest CT scan annually,
in the absence of clinical/radiographic evidence of disease.66
Consolidating the various published guidelines as
summarized above, a general approach to follow-up of
patients following SABR treatment should include physical assessment every 3–6 months during the initial year
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following treatment, followed by every 6–12 months for 3
years, then annually thereafter. Exact frequency and duration of follow-up can be left to the discretion of the treating
physician’s clinical assessment. For example, the presence
of CT findings on follow-up imaging may prompt more frequent imaging.
In the setting of suspicious findings on imaging, guidelines for follow-up of patients after SABR are currently lacking. A systematic follow-up imaging algorithm based on
HRFs and SUVmax thresholds based on current evidence is
available for reference and provides literature-based guidelines for management until further evidence becomes available.43 This algorithm combines high-risk CT features and
FDG-PET as tools for the prediction and accurate diagnosis
of local recurrence. Patients are categorized as having a low-,
intermediate-, or high-risk of recurrence based on the number of high-risk CT features present (no HRFs, 1–2 HRFs, or
≥ 3 HRFs, respectively). Subsequent management is based
on this risk stratification: low-risk patients with no HRFs can
be imaged every 3–6 months for 1 year, after which an imaging interval of 6–12 months can be considered; intermediaterisk patients with the presence of 1–2 HRFs can benefit from
an FDG-PET/CT if available and close follow-up; patients
at high-risk of recurrence with the presence of more than
three HRFs can be investigated with a biopsy or can proceed directly to salvage treatment. When available, SUVmax
values that are either greater than five, or exceeding pretreatment SUVmax values, trigger additional interventions including biopsy, resection, or nonsurgical salvage. Applicability
of this follow-up scheme depends on the specific clinical
scenario, and recommendations are expected to change as
more data becomes available. More rigorous follow-up and
early investigation for any suspicion of disease progression
may also be justified in patients with known pretreatment
risk factors for local recurrence such as larger lesions (T2),
suboptimal radiation dose, and perhaps high pretreatment
SUVmax.47,67,68
Whenever possible, lung cancer patients with suspicious
findings on radiographic follow-up scans who are amenable to
salvage treatment should be discussed by a multidisciplinary
team. Salvage surgery after SABR appears to be safe: at least
four small studies have reported on patients who have undergone surgery for salvage of a post-SABR recurrence.69–72
Across these four studies, such surgery is generally well tolerated with a favorable toxicity profile, with only one patient
sustaining a major toxicity (fistula requiring further surgery
for correction).71 Salvage repeat irradiation in the setting of
SABR has shown good outcomes in terms of local control,
and overall survival, although toxicity is likely higher, as
described above. Reirradiation with SABR as either primary
or salvage treatment resulted in local control rates ranging
from 65.5% to 75% at 1 year.62

Future Directions
The results of ongoing research in response assessment will continue to shape the optimal imaging and followup guidelines for lung cancer patients in the coming years.
Large studies examining patients with pathologic proof of

recurrence would be ideal to investigate and test new imaging
biomarkers. Given the relative uncommon clinical scenario of
local recurrence that is confirmed pathologically, multi-institutional efforts would be required to assemble such data. New
quantitative methods such as CT image feature analysis and
further characterization of posttreatment FDG-PET SUVs73
and other biologic markers are emerging.74,75 Ultimately, further study is needed to help reduce physician uncertainties in
imaging response assessment, which is becoming an increasingly critical aspect of survivorship for patients undergoing
SABR for NSCLC and their physicians within the multidisciplinary team.
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